Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Edwards Lifesciences Corp Director's Dealing 2012

Jul 10, 2012

30042_dirs_2012-07-10_f68ec0dc-66dd-4ce3-85fe-77f72ec8f906.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2012-07-10

Reporting Person: MUSSALLEM MICHAEL A (Director, Chairman & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-10 Common Stock M 35000.0000 $21.9550 Acquired 297568.0000 Direct
2012-07-10 Common Stock S 1100.0000 $103.5300 Disposed 296468.0000 Direct
2012-07-10 Common Stock S 8400.0000 $102.7000 Disposed 288068.0000 Direct
2012-07-10 Common Stock S 25500.0000 $101.7700 Disposed 262568.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-07-10 Employee Stock Option (Right to Acquire) $21.9550 M 35000.0000 Disposed 2013-05-10 Common Stock (35000.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 61965.0000 Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 9, 2012.

F2: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

F3: This transaction was executed in multiple trades at prices ranging from $103.51 to $103.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $102.44 to $103.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $101.43 to $102.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: Shares represented on the most recent statement of the 401(k) Plan Administrator where a unitized accounting procedure is utilized to convert the equities to share equivalents.